Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Up 38.9% in March

Gossamer Bio, Inc. (NASDAQ:GOSS - Get Free Report) was the target of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 7,970,000 shares, an increase of 38.9% from the March 15th total of 5,740,000 shares. Approximately 3.7% of the shares of the stock are sold short. Based on an average trading volume of 1,520,000 shares, the short-interest ratio is presently 5.2 days.

Analyst Ratings Changes

Several research analysts recently weighed in on GOSS shares. Wedbush reissued an "outperform" rating and issued a $4.00 target price on shares of Gossamer Bio in a research note on Friday, March 14th. HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Gossamer Bio in a report on Tuesday, March 18th. Finally, The Goldman Sachs Group reduced their price objective on shares of Gossamer Bio from $8.00 to $7.00 and set a "buy" rating on the stock in a research note on Thursday, April 17th.

Gossamer Bio Trading Up 8.9 %

NASDAQ GOSS traded up $0.07 during trading hours on Wednesday, hitting $0.90. 1,592,018 shares of the company's stock were exchanged, compared to its average volume of 1,570,603. The business's 50 day moving average is $1.13 and its 200-day moving average is $0.98. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74. Gossamer Bio has a 12-month low of $0.50 and a 12-month high of $1.55. The firm has a market capitalization of $204.68 million, a P/E ratio of -2.82 and a beta of 1.88.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last released its earnings results on Tuesday, March 18th. The company reported ($0.15) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.15). The company had revenue of $9.38 million during the quarter, compared to analyst estimates of $7.02 million. As a group, analysts anticipate that Gossamer Bio will post -0.28 EPS for the current fiscal year.

Institutional Trading of Gossamer Bio

Institutional investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. increased its position in shares of Gossamer Bio by 1.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,241,979 shares of the company's stock worth $1,123,000 after acquiring an additional 13,902 shares in the last quarter. Graham Capital Management L.P. acquired a new stake in Gossamer Bio in the 4th quarter valued at $32,000. Geode Capital Management LLC raised its position in Gossamer Bio by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 2,250,461 shares of the company's stock valued at $2,037,000 after purchasing an additional 38,084 shares during the period. Bank of America Corp DE lifted its stake in shares of Gossamer Bio by 107.2% during the fourth quarter. Bank of America Corp DE now owns 84,788 shares of the company's stock worth $77,000 after purchasing an additional 43,866 shares in the last quarter. Finally, Fullcircle Wealth LLC purchased a new stake in shares of Gossamer Bio in the fourth quarter worth about $43,000. 81.23% of the stock is owned by hedge funds and other institutional investors.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.